Inhibition of ATM Increases the Radiosensitivity of Uveal Melanoma Cells to Photons and Protons

In this study, our partners at the Liverpool Ocular Oncology Research Group (LOORG), investigated the differences between UM cells that are resistant to radiotherapy and the ones that are controlled with the same treatment. Their results suggest that the use of a specific drug named ATM inhibitors, which is already used for the treatment of other cancers, can improve the efficacity of radiotherapy in more resistant tumors.

Inhibition of ATM Increases the Radiosensitivity of Uveal Melanoma Cells to Photons and Protons

 

Radiation is one of the most common treatments for cancer. Other names for radiation therapy are radiotherapy or irradiation.It acts by damaging the cells, stopping their division. Since cancer cells grow and divide faster than most normal cells, nearby normal cells are less affected by radiation

For the treatment of uveal melanoma different mechanisms of radiotherapy are available, namely brachytherapy (where a plaque with radiation is placed in direct contact with the area of the eye where the cancer is) or proton beam therapy, that works by directing high amounts of energy to the cancer.

Radiotherapy is generally successful for UM, with eye tumour control being achieved in almost every case. Nonetheless, some UM tumors do not respond to radiotherapy, being a second treatment with radiation, or even enucleation (removal of the eye), needed.

In this study, our partners at the Liverpool Ocular Oncology Research Group (LOORG), investigated the differences between UM cells that are resistant to radiotherapy and the ones that are controlled with the same treatment. Their results suggest that the use of a specific drug named ATM inhibitors, which is already used for the treatment of other cancers, can improve the efficacity of radiotherapy in more resistant tumors.

You can access the full paper here.